Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07442292) titled 'PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor' on Feb. 24.

Study Type: Observational

Primary Sponsor: Peking University Cancer Hospital & Institute

Condition: Lung Cancer (NSCLC) Lung Cancer (SCLC) Melanoma (Skin Cancer) Melanoma Metastatic PD-L1 PET / CT

Recruitment Status: Not recruiting

Date of First Enrollment: February 2026

Target Sample Size: 40

To know more, visit https://clinicaltrials.gov/study/NCT07442292

Published by HT Digital Content Services with permission from Health Daily Digest....